291 related articles for article (PubMed ID: 29185393)
41. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Neelapu SS; Locke FL; Bartlett NL; Lekakis LJ; Miklos DB; Jacobson CA; Braunschweig I; Oluwole OO; Siddiqi T; Lin Y; Timmerman JM; Stiff PJ; Friedberg JW; Flinn IW; Goy A; Hill BT; Smith MR; Deol A; Farooq U; McSweeney P; Munoz J; Avivi I; Castro JE; Westin JR; Chavez JC; Ghobadi A; Komanduri KV; Levy R; Jacobsen ED; Witzig TE; Reagan P; Bot A; Rossi J; Navale L; Jiang Y; Aycock J; Elias M; Chang D; Wiezorek J; Go WY
N Engl J Med; 2017 Dec; 377(26):2531-2544. PubMed ID: 29226797
[TBL] [Abstract][Full Text] [Related]
42. CAR T Cells Releasing IL-18 Convert to T-Bet
Chmielewski M; Abken H
Cell Rep; 2017 Dec; 21(11):3205-3219. PubMed ID: 29241547
[TBL] [Abstract][Full Text] [Related]
43. Fine-Tuning of Optimal TCR Signaling in Tumor-Redirected CD8 T Cells by Distinct TCR Affinity-Mediated Mechanisms.
Presotto D; Erdes E; Duong MN; Allard M; Regamey PO; Quadroni M; Doucey MA; Rufer N; Hebeisen M
Front Immunol; 2017; 8():1564. PubMed ID: 29187853
[TBL] [Abstract][Full Text] [Related]
44. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
45. T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors.
Hu J; Sun C; Bernatchez C; Xia X; Hwu P; Dotti G; Li S
Clin Cancer Res; 2018 Jun; 24(12):2920-2934. PubMed ID: 29391351
[No Abstract] [Full Text] [Related]
46. Glycan-directed CAR-T cells.
Steentoft C; Migliorini D; King TR; Mandel U; June CH; Posey AD
Glycobiology; 2018 Sep; 28(9):656-669. PubMed ID: 29370379
[TBL] [Abstract][Full Text] [Related]
47. Posttransplant chimeric antigen receptor therapy.
Smith M; Zakrzewski J; James S; Sadelain M
Blood; 2018 Mar; 131(10):1045-1052. PubMed ID: 29358181
[TBL] [Abstract][Full Text] [Related]
48. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.
Guedan S; Posey AD; Shaw C; Wing A; Da T; Patel PR; McGettigan SE; Casado-Medrano V; Kawalekar OU; Uribe-Herranz M; Song D; Melenhorst JJ; Lacey SF; Scholler J; Keith B; Young RM; June CH
JCI Insight; 2018 Jan; 3(1):. PubMed ID: 29321369
[TBL] [Abstract][Full Text] [Related]
49. Developing T-cell therapies for lymphoma without receptor engineering.
Grant M; Bollard CM
Blood Adv; 2017 Dec; 1(26):2579-2590. PubMed ID: 29296911
[TBL] [Abstract][Full Text] [Related]
50. Fine and Predictable Tuning of TALEN Gene Editing Targeting for Improved T Cell Adoptive Immunotherapy.
Gautron AS; Juillerat A; Guyot V; Filhol JM; Dessez E; Duclert A; Duchateau P; Poirot L
Mol Ther Nucleic Acids; 2017 Dec; 9():312-321. PubMed ID: 29246309
[TBL] [Abstract][Full Text] [Related]
51. CARs on a highway with roadblocks.
Galluzzi L; Martin P
Oncoimmunology; 2017; 6(12):e1388486. PubMed ID: 29209574
[No Abstract] [Full Text] [Related]
52. CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.
Thayaparan T; Petrovic RM; Achkova DY; Zabinski T; Davies DM; Klampatsa A; Parente-Pereira AC; Whilding LM; van der Stegen SJ; Woodman N; Sheaff M; Cochran JR; Spicer JF; Maher J
Oncoimmunology; 2017; 6(12):e1363137. PubMed ID: 29209570
[TBL] [Abstract][Full Text] [Related]
53. Use of cord blood derived T-cells in cancer immunotherapy: milestones achieved and future perspectives.
Lo Presti V; Nierkens S; Boelens JJ; van Til NP
Expert Rev Hematol; 2018 Mar; 11(3):209-218. PubMed ID: 29359983
[TBL] [Abstract][Full Text] [Related]
54. CD19 CAR T Cells.
Sadelain M
Cell; 2017 Dec; 171(7):1471. PubMed ID: 29245005
[TBL] [Abstract][Full Text] [Related]
55. Short-term culture with IL-2 is beneficial for potent memory chimeric antigen receptor T cell production.
Zhang X; Lv X; Song Y
Biochem Biophys Res Commun; 2018 Jan; 495(2):1833-1838. PubMed ID: 29229383
[TBL] [Abstract][Full Text] [Related]
56. Cholesterol Esterification Enzyme Inhibition Enhances Antitumor Effects of Human Chimeric Antigen Receptors Modified T Cells.
Zhao L; Li J; Liu Y; Kang L; Chen H; Jin Y; Zhao F; Feng J; Fang C; Zhu B; Ding S; Yu L; Wei Y; Zhou J
J Immunother; 2018; 41(2):45-52. PubMed ID: 29252915
[TBL] [Abstract][Full Text] [Related]
57. A Milestone for CAR T Cells.
Tran E; Longo DL; Urba WJ
N Engl J Med; 2017 Dec; 377(26):2593-2596. PubMed ID: 29226781
[No Abstract] [Full Text] [Related]
58. CAR-T cells and combination therapies: What's next in the immunotherapy revolution?
Ramello MC; Haura EB; Abate-Daga D
Pharmacol Res; 2018 Mar; 129():194-203. PubMed ID: 29203440
[TBL] [Abstract][Full Text] [Related]
59. Human antibody-based chemically induced dimerizers for cell therapeutic applications.
Hill ZB; Martinko AJ; Nguyen DP; Wells JA
Nat Chem Biol; 2018 Feb; 14(2):112-117. PubMed ID: 29200207
[TBL] [Abstract][Full Text] [Related]
60. Developing T-cell therapies for lymphoma without receptor engineering.
Grant M; Bollard CM
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):622-631. PubMed ID: 29222313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
